Perspectives of the diagnosis of Alzheimer’s disease using optic coherent tomography

Close metadata

Recommended articles:

Glymphatic dysfunction and sleep disorders: indirect effects on Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):7-12

Ginkgolide B: mechanisms of neurobiological effects, prospects for use in the therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):22-27

Associations of serum neuromarkers with clinical features of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):145-152

Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24

Impairment of attention and executive functions in chronic cerebrovascular disease and Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):25-32

Assessment of the significance of dilated perivascular spaces and nocture arterial hypertension in the development of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):33-40

EEG changes in patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):72-76

Predicting the effectiveness of organ-preserving treatment of choroidal melanoma using optical coherence tomography data. Russian Annals of Ophthalmology. 2024;(2-2):16-20

Outcomes of bimanual vitreoretinal surgery in the treatment of diabetic retinopathy complications. Russian Annals of Ophthalmology. 2024;(2-2):21-27

Application of optical coherence tomography in the assessment of the posterior lens capsule during anti-angiogenic therapy. Russian Annals of Ophthalmology. 2024;(2-2):28-33

There is a constant search for new possibilities of the diagnosis of neurodegenerative diseases that cause dementia. The problem is important because of the growing prevalence of dementia, 60—80% of which are caused by Alzheimer’s disease (AD). Over the last years, changes in the retina are thought to be a marker neurodegeneration. Assessment of these changes is performed using a method of optical coherent tomography (OCT) that allows taking cross-sectional imaging of a tissue. OCT is considered a potential biomarker of the early stage of AD. Identification of the relationship of the changes in retina and the optic nerve with cognitive impairment open new possibilities for the diagnosis of AD.

Keywords:

Alzheimer’s disease

neurodegeneration

biomarker

retina

optical coherent tomography

Authors:

Bogolepova A.N.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Moskva

SPIN RSCI: 6775-0279
Scopus AuthorID: 6602240836
ORCID: 0000-0002-6327-3546

Zhuravleva A.N.

Helmholtz Moscow Research Institute of Eye Diseases, Moscow, Russia

Makhnovich E.V.

Pirogov Russian National Research Medical University, Moscow, Russia

List of references:

World Alzheimer Report 2015. The Global Impact of Dementia An analysis of prevalence, incidence, cost and trends. Published by Alzheimer`s Disease International (ADI), London 2015. http://www.dementiaallianceinternational.org/wp-content/uploads/2015/08/World-Alzheimer-Report-2015-Summary-2015.
Beloysov YB, Zarinov SK, Beloysov DY, Beketov AS. Clinical and economic aspects of therapy of Alzheimer’s disease in Russia. Good clinical practice. 2009;1:3-28. (In Russ.).
Dementia: A public health priority. Geneva WHO; 2012;102. http://www.who.int/mental_health/publications/dementia_report_2012/en/
International statistical classification of diseases and problems related to health. Tenth revision (ICD-10). Vol. 1 (part 1). Geneva: WHO; 1995. (In Russ.).
McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939-944.
Knopman DS, Parisi JE, Salviati A. Neuropathology of cognitively normal elderly. J neuropathol exp neurol. 2003;62(11):1087-1095.
Davis DG, Schmitt FA, Wekstein DR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J neuropathol exp neurol. 1999;58(4):376-388.
Bennett DA, Schneider JA, Arvanitakis Z. Neuropathology of older persons without cognitive impairment from two community — based studies. Neurology. 2006;66(12):1837-1844.
Jack CR, Albert MS, Knopman DS. Introduction to the recommendations from the National Institute on Aging—Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheim dement. 2011;7(3):257-262.
Sperling RA, Aisen PS, Beckett LA. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging—Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheim dement. 2011;7(3):280-292.
Dubois B, Feldman H, Jacova C. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet neurol. 2010;9(11):1118-1127.
Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer`s disease. Invest Ophthalmol Vis Sci. 2007;48:2285-2289.
Borson S, Barnes RF, Veith RC, Halter JB, Raskind MA. Impaired sympathetic nervous system response to cognitive effort in early Alzheimer`s disease. J Gerontol. 1989;44:8-12.
Albert MS, DeKosky ST, Dickson D. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging—Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheim Dement. 2011;7(3):270279.
Emelin A.Y., Odinak M.M., Tryfanov G.E. Possibilities of positron emission tomography in the differential diagnosis of dementia. Vestn Growing Military Acad med/ 2010;4(32):46-51. (In Russ.).
Blennow K, Hampel H, Weiner M. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat rev neurol. 2010;6(3):131-144.
Mintun MA, Larossa GN, Sheline YI. PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.
Stern Y. Cognitive reserve. Neuropsychologia. 2009;47:2015-2028.
Tapiola T, Alafuzoff I, Herukka SK. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer — type pathologic changes in the brain. Arch neurol. 2009;66(3):382-389.
Odinac MM, Emelina AYu, Dekan VS. Modern possibilities of neuroimaging in the diagnosis of dementia. Psychiatry. 2009;1(37):57-61. (In Russ.).
Odinac MM, Emelina AYu, Lobzin VY. Cerebral perfusion and cognitive impairment in patients with vascular dementia. Med Acad Journ. 2011;11(1):58-64. (In Russ.).
Atiya M, Hyman B, Albert M. Structural magnetic resonance imaging in established and prodromal Alzheimer’s disease: a review. Alzheim dis ass dis. 2003;17(3):177-195.
Jagust W. Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia. Alzheim dement. 2006;2(1):36-42.
Kantarci K, Jack C. Neuroimaging in Alzheimer’s disease: an evidenced — based review. Neuroimag clin north am. 2003;13(2):197-209.
Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer’s disease. Lancet Neurology. 2004;3:246-248.
McKhann GM, Knopman DS, Chertkow H. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging—Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheim dement. 2011;7(3):263-269.
Armstrong RA. Visual field defects in Alzheimer`s disease patients may reflect differential pathology in the primary visual cortex. Optom Vis Sci. 1996;73:677-682.
Gasser P. Ocular vasospasm: a risk factor in the pathogenesis of low-tension glaucoma. Int Ophthalmol. 1989;13(4):281-290.
Hof PR, Morrison JH. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer`s disease: II. Primary and secondary visual cortex. J Comp Neurol. 1990;301:55-64.
Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011;54(1):204-217.
Cronin-Golomb A, Corkin S, Rizzo JF, Cohen J, Growdon JH, Banks KS. Visual dysfunction in Alzheimer`s disease: relation to normal aging. Ann Neurol. 1991;29:41-52.
Pache M, Smeets CH, Gasio P, Savaskan E, Flammer J, Wirz-Justice A. Colour vision deficiencies in Alzheimer`s disease. Age Ageing. 2003;32:422-426.
Gilmore GC, Whitehouse PJ. Contrast sensitivity in Alzheimer`s disease: a 1-year longitudinal analysis. Optom Vis Sci. 1995;72:83-91.
Iseri PK, Altinas O, Tokay T, Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functionalabnormalities in Alzheimer`s disease. J of Neuro Ophthal. 2006;26:18-24.
Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F. Morphological and functional retinal impairment in Alzheimer`s disease patients. Clin Neurophysiol. 2001;112:1860-1867.
Granholm E, Morris S, Galasko D, Shults C, Rogers E, Vukov B. Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer`s and Parkinson`s disease. Int J Psychophysiol. 2003;47:95115.
Graff-Radford NR, Lin SC, Brazis PW, Bolling JP, Liesegang TJ, Lucas JA. Tropicamide eyedrops cannot be used for reliable diagnosis of Alzheimer`s disease. Mayo Clin Proc. 1997;72:495-504.
Takagi A, Miyao M, Ishihara S, Sakakibara H, Kondo T, Toyoshima H. Sensitive pupil response of early-onset Alzheimer`s patients to a dilute mixture of cholinergic antagonist and alpha-Adrenergetic stimulant. Environ Health Prev Med. 1999;4:49-53.
Prettyman R, Bitsios P, Szabadi E. Altered papillary size and darkness and light reflexes in Alzheimer`a disease. J Neurol Neurosurg Psychiarty. 1997;62:665-668.
Partanen J, Hartikainen P, Könönen M, Jousmäki V, Soininen H, Riekkinen PSr. Prolonged latencies of pattern reversal visual evoked early potentials in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994;8(4):250-258.
Pollock VE, Schneider LS, Chui HC, Henderson V, Zemansky M, Sloane RB. Visual evoked potentials in dementia: a meta-analysis and empirical study ofAlzheimer’s disease patients. Biol Psychiatry. 1989;25(8):1003-1013.
Krasodomska K, Lubiński W, Potemkowski A, Honczarenko K. Pattern electroretinogram (PERG) and pattern visual evoked potential (PVEP) in the early stages of Alzheimer’s disease. Doc Ophthalmol. 2010;121(2):111-121.
Kergoat H, Kergoat M, Justino L, Chertkow H, Robillard A, Bergman H. An evaluation of the retinal nerve fiber layer thickness by scanning laser polarimetry in individuals with dementia of the Alzheimer`s type. Acta Ophthal Scand. 2001;79:187-191.
Rizzo JF, Cronin-Golomb A, Growdon JH, Corkin S, Rosen TJ, Sandberg MA, Chiappa KH, Lessell S. Retinocalcarine function in Alzeimer`s disease: a clinical and electrophysiological study. Arch Neurol. 1992;49:93-101.
Lewis DA, Campbell MJ, Terry RD, Morrison JH. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer`s disease: a quantitative study of visual and auditory cortices. J Neurosc.1987;7:1799-1808.
Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic nerve degeneration in Alzheimer`s disease. N Engl J Med. 1986;315:485-487.
Liu B, Rassol S, Yang Z, Glabe CG, Schreiber SS, Ge J. Amyloid-peptide vaccinations reduce beta-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer`s transgenic mice. Am J Pathol. 2009;16:30-39.
Bull ND, Guidi A, Goedert M, Martin KR, Spillantini MG. Reduced axonal transport and increased excitotoxic retinal ganglion cell degeneration in mice transgenic for human mutant P301S tau. PLoS One. 2012;7:34724.
Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011;54(1):204-217.
Trick GL, Trick LR, Morris P, Wolf M. Visual field loss in senile dementia of the Alzheimer`s disease type. Neurology. 1995;45:68-74.
Valenti DA. Alzheimer’s Disease: Screening Biomarkers Using Frequency Doubling Technology Visual Field. ISRN Neurology. 2013Article ID 989583.
Greenberg BM, Frohman E. Optical coherence tomography as a potential readout in clinical trials. Ther Adv Neurol Disord. 2010;3(3):153-160.
Yavas GF, Yilmaz O, Küsbeci T, Oztürk F. The effect of levodopa and dopamine agonists on optic nerve head in Parkinson disease. Eur J Ophthalmol. 2007;17(5):812-816.
Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer`s disease. Neurosci Letter. 2007;420(2):97-99.
Blanks JC, Torigoe Y, Hinton DR, Blanks RH. Retinal pathology in Alzheimer`s disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging. 1996;17:377-384.
Chi Y, Wang YH, Yang L. The investigation of retinal nerve fiber loss in Alzheimer`s disease. Zhonghua Yanke Zazhi. 2010;46(2):134-139.
Deng YL, Chen Y, Xie LQ. Morphological change of retina in mild Alzheimer`s disease. Zhenduanxue Lilun Yu Shijian. 2009;8:397-400.
Lu Y, Li Z, Zhang H. Retinal nerve fiber layer structure abnormalities in early Alzheimer`s disease: evidence in optical coherence tomography. Neurosci Letters. 2010;480(1):69-72.
Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer`s disease. Ophthalmol. 1990;97:9-17.
Ericheva VP, Panyshkina LA, Fomina AV. Optical coherence tomography of the retina and optic nerve in the diagnosis of Alzheimer’s disease. Ophthalmology. 2013;1:5-11. (In Russ.).
Danesh-Meyer HV, Birch H, Ku JY, Carroll S, Gamble G. Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology. 2006;67(10):1852-1854.
Tiganov AS, Acopian VS, Gavrilova SI, Semenova NS, Fedorova IB, Gyrova EV. Nanoarchitectonics retina of patients with Alzheimer’s disease and the syndrome of mild cognitive impairment (preliminary results). Ophthalmology. 2012;9:434-436. (In Russ.).

Close metadata